UK Artificial Intelligence (AI) in Medical Imaging market size was valued at $39 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 33.4% from 2022 to 2030 and will reach $391 Mn. The market is segmented by AI technology, solution, modality, application, and end User. The UK Artificial Intelligence (AI) in the Medical Imaging market will grow because AI technologies can help improve the accuracy and efficiency of medical imaging, leading to better patient outcomes and reduced healthcare costs. Some of the key players in this market are Optellum, Kheiron Medical, Aidoc, Sophia Genetics, Ultromics, Brainomix, MaxQ AI, Faculty, Sensyne Health, Feedback Medical, Cambridge Medical Imaging, Perspectum, Oxipit, Qure.ai, Quantib, Imagen, Mirada Medical, Kromek Group, GTN, 4D Imaging, and others.
UK alzheimer’s therapeutics market valued at $125 Mn in 2022, projected to reach $216 Mn by 2030 with a 7.1% CAGR. One key factor propelling the market for Alzheimer's treatment medications is the rising incidence of Alzheimer's disease which is driven by an aging population. Biogen, Eisai Co, Janssen Pharmaceuticals, Novartis, Pfizer, Lundbeck, Merck & Co, AstraZeneca, Eli Lilly and Accord Healthcare are leading pharmaceutical companies currently operating in the market.
UK Infectious Disease Drugs Market valued at $3.08 Bn in 2023, projected to reach $3.61 Bn by 2030 with a 2.27% CAGR. Rising antimicrobial resistance, technological advancements, government initiatives, and funding are some of the factors driving the market. The market is dominated by key players like GlaxoSmithKline plc, AstraZeneca, AbbVie Inc., Gilead Sciences, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Novartis AG, and Sanofi S.A.
The UK Atopic Dermatitis Therapeutics Market was valued at US $320 Mn in 2022, and is predicted to grow at (CAGR) of 6.8% from 2023 to 2030, to US $541 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), evolving treatment landscape of the industry, and high medical unmet needs and diagnoses. The industry is primarily dominated by players such as Pfizer, Astellas, Novartis, Galderma, AbbVie, Anacor, Meda, and Allergan, among others.
UK Atherosclerosis Therapeutics Market was valued at $73 Mn in 2022 and is estimated to reach $97 Mn in 2030, exhibiting a CAGR of 3.7% during the forecast period. The market for atherosclerosis therapeutics is expected to rise as a result of the increasing prevalence of cardiovascular illnesses that have been exacerbated by unhealthy eating habits, sedentary lifestyles, and an aging population worldwide. The top leading pharmaceutical companies presently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Merck & Co., Janssen Pharmaceuticals, Bayer, Abbott, Eli Lilly and Roche.
The UK Asthma and COPD Therapeutics Market was valued at US $0.868 Bn in 2022, and is predicted to grow at (CAGR) of 3.20% from 2023 to 2030, to US $1.117 Bn by 2030. The key drivers of this industry include the surge in the prevalence of COPD and asthma, demand for effective treatment, supportive government initiatives, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Teva, GSK, Novartis Pfizer, Boehringer Ingelheim, among others
UK HIV Drugs Market is at around $0.82 Bn in 2023 and is projected to reach $0.92 Bn in 2030, exhibiting a CAGR of 1.6% during the forecast period. Government initiatives, increased access to healthcare, and international partnerships are driving the sector. The market is dominated by key players like ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd, Johnson & Johnson, and Bayer.
UK Antifungal Drugs Market is at around $0.4 Bn in 2023 and is projected to reach $0.5 Bn in 2030, exhibiting a CAGR of 1.8% during the forecast period. The rise in the market is being driven by the rising prevalence of fungal infections, improvements in healthcare infrastructure, and technological advancements in drug development. The market is dominated by key players like Merck & Co., Inc., Pfizer Inc., Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
UK Dengue Vaccines Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The increasing dengue burden globally, growing awareness and government initiatives, technological advancements in vaccine development, economic burden reduction, and collaborative efforts between vaccine manufacturers, research organisations, and government agencies are driving the Dengue Vaccines market. Sanofi Pasteur, Takeda Pharmaceutical Company Limited, Butantan Institute, Biological E. Limited, Merck & Co., Bharat Biotech International Limited, Panacea Biotec Limited, GlaxoSmithKline plc, GeneOne Life Science Inc., Inviragen (a subsidiary of Takeda Pharmaceutical Company Limited) are among the global key players in Dengue Vaccines Market.
UK Depression/Major Depressive Disorders (MDD) Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Factors driving the Depression/Major Depressive Disorders (MDD) market include rising global depression prevalence, increased awareness and understanding of mental health issues, advancements in treatment options such as new medications and therapies, rising healthcare expenditure and insurance coverage for mental health, and government initiatives aimed at improving mental healthcare access. Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Company, H. Lundbeck A/S, Merck & Co., Inc., Allergan plc are global key players in Depression/Major Depressive Disorders (MDD) Market.
UK Diabetes Management Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Diabetes management market drivers include rising diabetes prevalence, technological advancements in glucose monitoring and insulin delivery systems, increased diabetes awareness and education, government initiatives promoting diabetes management, and rising healthcare expenditure on chronic disease management. Medtronic plc, Abbott Laboratories, Dexcom, Roche Diabetes Care, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Johnson & Johnson, Ascensia Diabetes Care Holdings AG, Becton, Dickinson and Company are global key players in Diabetes Management Market.
UK Diabetic Retinopathy Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The increasing prevalence of diabetic retinopathy, technological advancements in drug development, growing awareness and screening programmes, the ageing population, and government initiatives to improve access to screening and treatment for diabetic retinopathy are the drivers of the Diabetic Retinopathy Drugs market. Novartis AG, Regeneron Pharmaceuticals, Allergan plc (part of AbbVie Inc.), Roche Holding AG, Pfizer Inc., Bayer AG, Santen Pharmaceutical Co., Ltd., Johnson & Johnson, Bausch Health Companies Inc., Alimera Sciences, are key global companies in diabetic retinopathy drugs market.
UK Diabetic Retinopathy Therapeutic Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Increasing prevalence of diabetes, growing awareness and early diagnosis, advancements in technology and treatment options, government initiatives and healthcare expenditure, and the aging population are the drivers of the diabetic retinopathy therapeutic market. Prominent global players in the market include Novartis AG, Roche Holdings AG, Regeneron Pharmaceuticals, Bayer AG, Allergan plc (AbbVie Inc.), Alimera Sciences, Bausch Health Companies Inc., Topcon Corporation, Carl Zeiss Meditec AG and NIDEK Co., Ltd.
UK Drugs Addiction Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The drug addiction market is driven by rising substance usage, increased awareness and public health campaigns, breakthroughs in treatment methods, government initiatives and legislation, and the high frequency of co-occurring mental health issues. Indivior PLC, Alkermes plc, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Orexo AB, Mylan N.V., Glenmark Pharmaceuticals, Accord Healthcare Ltd., and Camurus AB are global players in the Drug Addiction Market.
UK Dry Eye Medication Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Increasing prevalence of dry eye, aging population, technological advancements in drug formulations and diagnostics, rising awareness and diagnosis, and lifestyle factors such as increased screen time and air pollution are the drivers of the dry eye medication market. Allergan plc (AbbVie Inc.), Novartis AG, Santen Pharmaceutical Co., Ltd., Johnson & Johnson, Bausch Health Companies Inc., Alcon, Inc. (a division of Novartis AG), Sun Pharmaceutical Industries Ltd., Otsuka Holdings Co., Taisho Pharmaceutical Co., Ltd, Senju Pharmaceutical Co. Are global companies in Dry Eye Medication Market.
UK Encephalitis Vaccines Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Increasing incidence of encephalitis, growing awareness and immunization programs, technological advancements in vaccine development, global travel and migration, and government support and funding are the drivers of the encephalitis vaccines market. GlaxoSmithKline plc, Sanofi Pasteur, Pfizer Inc., Merck & Co., Novartis AG, Bharat Biotech International Ltd., Takeda Pharmaceutical Company Limited, Biological E. Limited, Valneva SE and Sinovac Biotech Ltd are global companies in encephalitis vaccines market.
UK End-stage renal disease (ESRD) Market Analysis is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Drivers of the End-stage renal disease (ESRD) market include the increasing prevalence of chronic kidney diseases, advancements in renal replacement therapies, growing demand for kidney transplantation, government initiatives and healthcare policies supporting renal care, and the aging population. Global Players in the ESRD Market are Fresenius Medical Care AG & Co. KGaA, DaVita Inc., Baxter International Inc., B. Braun Melsungen AG, Nipro Corporation, Nikkiso Co., Ltd., Asahi Kasei Medical Co., Ltd., Medtronic plc, Terumo Corporation and Rockwell Medical, Inc.
UK Endometriosis Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Drivers of the Endometriosis Drugs market include the increasing prevalence of endometriosis, growing awareness and diagnosis, demand for effective pain management, technological advancements in drug development, and supportive government initiatives. These factors contribute to market growth by addressing unmet needs and improving access to treatment options for endometriosis patients. Global Players in the Endometriosis Drugs Market are AbbVie Inc., Pfizer Inc., Bayer AG, Eli Lilly and Company, Johnson & Johnson, AstraZeneca PLC, Novartis International AG, Teva Pharmaceutical Industries Ltd., Merck & Co. and Takeda Pharmaceutical Company Limited.
UK Enzymatic Wound Debridement Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Growing prevalence of chronic wounds and diabetic ulcers, Advancements in enzymatic debridement technology, increasing demand for non-invasive and painless wound debridement methods and rising geriatric population prone to chronic wounds are drivers in Enzymatic Wound Debridement Market. Global Companies in the Enzymatic Wound Debridement Market are Smith & Nephew plc, Mölnlycke Health Care AB, B. Braun Melsungen AG, Coloplast A/S, ConvaTec Group plc, Paul Hartmann AG, Hollister Incorporated, Integra LifeSciences Corporation, Organogenesis Inc. and Misonix Inc.
UK Enzyme Inhibitors Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The growing prevalence of enzyme-related disorders, advances in drug discovery and development, a greater emphasis on personalized therapy, and increased research spending and collaborations are driving the enzyme inhibitors market. Novartis International AG, Roche Holding AG, AstraZeneca PLC, GlaxoSmithKline plc, Sanofi S.A., Boehringer Ingelheim International GmbH, Bayer AG, Takeda Pharmaceutical Company Limited, AbbVie Inc., and Merck KGaA are the global participants in the enzyme inhibitors market.
UK Epigenetics Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Factors driving this market growth include an increase in the incidences of infectious diseases, cancer, chronic conditions, and genetic conditions; rising healthcare spending, which, according to the American Medical Association, will exceed $187.6 billion in 2021; and growing interest in bioinformatics, the market for which will reach $10 billion in revenue in 2022. Global key players in the epigenetics market include Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Merck KGaA, and Abcam plc.
UK Epilepsy Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rising prevalence of epilepsy, increasing incidences of brain cancer in the geriatric population, and extensive research and development (R&D) activities represent some of the key factors driving the market. Some of the prominent global players in the epilepsy drugs market include Pfizer Inc., UCB S.A., GlaxoSmithKline plc, Novartis AG, and Eisai Co., Ltd.
UK Gastroesophageal Reflux Disease (GERD) Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The high prevalence of GERD, rising awareness and diagnostic rates, technology improvements, and lifestyle variables are all driving factors in the Gastroesophageal Reflux Disease (GERD) medications market. Some prominent global players in the Gastroesophageal Reflux Disease (GERD) drugs market include AstraZeneca PLC, Pfizer Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Company, AbbVie Inc., Mylan N.V., Perrigo Company plc, and Sun Pharmaceutical Industries Ltd.
UK Gastrointestinal Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rising prevalence of gastrointestinal problems, caused by factors such as changing lifestyles, dietary habits, and an ageing population, is one of the main drivers for gastrointestinal medications. Technological advances in drug research and targeted medicines, which provide more effective treatment alternatives, also contribute to market growth. Furthermore, as people become more aware of and diagnose gastrointestinal diseases, the need for medications to treat these conditions grows. Pfizer Inc., Johnson & Johnson, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, GlaxoSmithKline plc, Bristol Myers Squibb Company, Eli Lilly and Company, Merck & Co., Inc., and Allergan plc are among the major global competitors in the gastrointestinal drugs market.
UK Generic and Biosimilar Pharmaceutical Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The generic and biosimilar pharmaceutical market is driven by cost-effectiveness, patent expirations, rising healthcare demand, and government cost-cutting initiatives. Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH (Novartis), Pfizer Inc., Amgen Inc., Biocon Ltd., Dr. Reddy's Laboratories Ltd., Fresenius Kabi AG, Celltrion Inc., and Stada Arzneimittel AG are global companies in the Generic and Biosimilar Pharmaceutical Market.